Agenus to present 3-year colorectal cancer survival data at ESMO GI

June 25, 2026 7:00 AM

Agenus Inc. (Nasdaq: AGEN) will present three-year survival data from a Phase 1b clinical study of botensilimab (BOT) combined with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found